New Blood test for Parkinson’s is being studied

The company Durin Technologies has identified a panel of protein biomarkers in the blood of Parkinson?s disease subjects that seem to be different compared to controls and Alzheimer?s disease. It is unknown whether the proteins change with the course of the disease but the Michael J. Fox Foundation is supporting the company to verify these results in samples collected in the DATATOP clinical trial to explore this question. If results are promising, the PPMI cohort would be a good sample set in which to verify the observation and build the dataset for the biomarker panel.

New Blood Test for Parkinson’s Studied
Test Has High Degree of Accuracy; Parkinson?s Experts Cautiously Optimistic
By Kathleen Doheny
WebMD Health News

Feb. 22, 2012 — An experimental blood test for Parkinson’s disease is more than 90% accurate in diagnosing the progressive disorder that affects movement and balance, according to its developers.

The test requires a single drop of blood, says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.

It looks for specific proteins that are produced by the body in response to Parkinson’s disease, he tells WebMD.

Nagele is also the founder of Durin Technologies, the test developer. Another co-researcher is a paid consultant for the company.

No blood test is yet commercially available for Parkinson’s, which affects 5 million people worldwide. The study is published in PLoS One.

The news was met with cautious optimism by two experts.
About Parkinson’s

In Parkinson’s, the nerve cells or neurons in a brain region responsible for muscle movement and coordination deteriorate over time. Normally these cells produce a chemical called dopamine. Dopamine helps regulate such bodily functions as movement.

“Parkinson’s affects a specific part of the brain known as the substantia nigra,” Nagele says. At least a third of the neurons in this area have already died before symptoms appear, he says.

Symptoms include shaking, tremor, slowness of movement, stiffness in the arms, legs, and trunk, and balance problems.

Doctors diagnose it by taking a medical history and doing a neurological exam.

A blood test could help doctors diagnose and treat the disease earlier. Many teams are working on such tests.
Blood Test for Parkinson’s: Study Details

When brain cells die, Nagele says, they explode ”like a water balloon breaking.”

The contents of those dying cells spill partially back into the blood. “Their debris is released and your body will sense it and develop autoantibodies to clear that debris,” he says.

The new test looks for these autoantibodies in the blood specific to the disease. The researchers narrowed down a list of more than 100 of these autoantibodies to 10 that looked most promising. When these antibodies rise to a certain level, it signals disease, Nagele says.

To evaluate the Parkinson’s test, Nagele’s team looked at more than 150 blood samples, including:

Twenty-nine from patients with confirmed Parkinson’s disease
Fifty from Alzheimer’s disease patients
Ten from multiple sclerosis patients
Thirty from breast cancer patients
Forty from healthy patients

Overall, the test identified 93% of those who had Parkinson’s. It identified correctly 100% of those who did not have it. Both results are considered important.

It could tell the difference between blood samples from patients with Parkinson’s, those with the other disorders, and those who were healthy.

Nagele estimates the test, when and if available, would cost about $200.

The new research is a ”proof of principle” study, he says, and much more research is needed.

Click here to continuing reading this article on WebMD.com.